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The LIAISON system is a fully automated system based on chemiluminescence and antigen bound to
magnetic microparticles. The system allows fast and precise measurement of Toxoplasma-specific immuno-
globulin G (IgG) and IgM antibody levels and measurement of the IgG avidity index even at low levels of
Toxoplasma-specific IgG antibodies in a single step without manual interference. Seven European centers
participated in a multicenter evaluation of the LIAISON system. The sensitivity and specificity of the LIAISON
system compared to the Sabin-Feldman dye test were 99.3 and 96.8%, respectively. In a comparison of the
LIAISON Toxoplasma-specific IgM assay with an immunosorbent agglutination assay, the LIAISON assay had
a sensitivity of 96.7% and a specificity of 95.4%. The LIAISON IgG assay showed agreements of 91, 100, and
100% with the AXSYM IgG (Abbott), VIDAS IgG (bioMérieux), and Platelia IgG (Bio-Rad) assays, respec-
tively. The LIAISON IgM assay showed agreements of 95% with the AXSYM IgM and Platelia IgM assays, 96%
with the ISAGA IgM assay (bioMérieux), and 97% with the VIDAS IgM assay. The coefficient of correlation
between the LIAISON system and the VIDAS Toxoplasma-specific IgG avidity index was 0.81. By use of the
Toxoplasma-specific IgG avidity index assay with specific IgM-positive samples, the diagnosis of infection with
Toxoplasma gondii in early pregnancy has been improved significantly. The LIAISON avidity assay is a valuable
assay for the exclusion of recently acquired infection with T. gondii (less than 4 months) in pregnant women,
and it decreases significantly the necessity for follow-up testing.
Primary maternal infection with Toxoplasma gondii carries
the risk of transmitting the infection to the fetus, resulting in
congenital infection. Congenital infection of the fetus in
women infected just before conception is extremely rare, and
even during the first few weeks of pregnancy, the maternal-
fetal transmission rate is low (6). It is therefore essential to
estimate the time of infection as precisely as possible to prop-
erly manage the risk to the fetus of a maternal infection. Low
levels of Toxoplasma-specific immunoglobulin M (IgM) anti-
bodies may be found for up to several years, and the mere
demonstration of low levels of Toxoplasma-specific IgM anti-
bodies is therefore not a sign by itself of acute infection with T.
gondii (16, 17). The measurement of the avidity of IgG anti-
bodies for T. gondii infections was first demonstrated in 1989
(8, 9, 15) and since then has been further developed (4, 18).
A study of the diagnostic value of various tests for acute
infections with T. gondii, including Toxoplasma-specific IgG,
IgM, and IgA antibodies and the IgG avidity index, showed
that the combination of a sensitive test for Toxoplasma-specific
IgM antibodies and a Toxoplasma-specific IgG avidity assay
had the highest predictive value with regard to the time of in-
fection (23).
Since previous studies showed that some individuals have
low-avidity IgG antibodies many months after infection, we
also tested the hypothesis of whether treatment influences the
maturation of IgG antibodies.
The LIAISON diagnostic system (DiaSorin, Saluggia, Italy)
is the first fully automated immunoassay based on chemilumi-
nescence and antigen bound to magnetic microparticles. It is
the first assay to allow measurement of the Toxoplasma-specific
IgG avidity index at low levels of specific IgG antibodies.
The aim of this study was to validate the LIAISON system in
European reference laboratories with the specific aims of val-
idating the automated measurement of the Toxoplasma-spe-
cific IgG avidity index and to study whether treatment influ-
ences the maturation of the IgG response.
METHODS AND MATERIALS
Samples and patients. Each center contributed samples according to the
categories of patients available; in total, 1,488 samples were included. Each
center had a LIAISON system available in the participating laboratories for the
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study. Centers involved in prenatal screening contributed samples from women
showing seroconversion. All samples were randomized. The test populations
were defined by how the centers performed screening, as follows: prenatal
screening every month (Paris and Pavia), screening every 3 months during preg-
nancy (Brussels and Seville), neonatal screening (Copenhagen), and no screen-
ing (Berlin and Swansea). In centers with no prenatal screening, populations
were defined based on their profiles in various serological tests.
(i) Seville, Spain. A total of 157 samples were tested with the LIAISON system
for Toxoplasma-specific IgG and IgM antibodies and the IgG avidity index. These
included 41 samples from patients with acute infections and a known time of
seroconversion within the preceding 4 months, 78 samples from patients in the
convalescence phase (infections acquired between 4 and 12 months before), 25
samples from patients in the latent phase (positive for Toxoplasma-specific IgG
for at least 12 months), and 13 samples from Toxoplasma-seronegative patients.
(ii) Berlin, Germany. The samples tested included 20 samples from patients
with recent infections (high Sabin-Feldman dye test result, positive for IgM, and
low avidity index), 13 samples from patients who were positive for IgG and IgM
and had a high avidity index, 14 samples from patients who were positive for IgG
and negative for IgM, and 92 samples from IgG- and IgM-negative patients. The
samples were tested with the AXSYM system (Abbott, Chicago, Ill.) (5), the
VIDAS system (bioMérieux, Marcy l’Etoile, France) (19), and the Sabin-Feld-
man dye test.
(iii) Brussels, Belgium. The samples tested included 67 samples from women
with acute infections and a known time of seroconversion, 38 samples from
patients with previous infections and no IgM, 43 samples from patients who had
a low level of IgG and who were positive for Toxoplasma-specific IgM antibodies,
and 33 samples from seronegative patients. Routine testing was performed by
use of assays from Bio-Rad (Marnes-la-Coquette, France) (12).
(iv) Copenhagen, Denmark. A total of 291 consecutive samples submitted
from hospitals and general practitioners were tested with the VIDAS and LIAI-
SON systems for Toxoplasma-specific IgG and IgM antibodies and the IgG
avidity index.
(v) Paris, France. A total of 435 samples were used in the study. These
included 67 samples obtained from patients with acute infections within 2 to 6
months after infection onset, 62 serial samples from 17 patients who had sero-
converted, 160 samples from patients with past infections (80 of which had
persistent IgM antibodies and 80 of which were negative for IgM), 120 samples
from seronegative patients, and 26 samples from 9 patients with previous infec-
tions and showing a serological reactivation. Routine testing was performed with
the VIDAS enzyme-linked immunosorbent assay, the VIDAS IgG avidity test,
the ISAGA IgM assay (bioMérieux), the Sabin-Feldman dye test, and the dif-
ferential agglutination assay (4, 7).
(vi) Pavia, Italy. A total of 55 consecutive samples from 17 patients with acute
infections, 32 samples from patients with recent infections, 62 samples from
patients with past infections, and 94 samples from seronegative patients were
included. Twenty samples from individuals who were not pregnant and who were
not treated were also included. Routine testing was performed with the VIDAS
IgG assay and IgG avidity assay, the ISAGA IgM assay, and the direct aggluti-
nation assay (bioMérieux).
(vii) Swansea, United Kingdom. A total of 181 samples were tested with
in-house assays and the LIAISON system for Toxoplasma-specific IgG and IgM
antibodies and the IgG avidity index. These included 18 samples from patients
with acute infections, 90 samples from patients with recent infections (65 of
which were tested for the IgG avidity index), 40 samples from patients with past
infections, and 33 samples from seronegative patients. Twelve samples from
individuals who were not pregnant and who were not treated were also included.
The laboratory used in-house enzyme-linked immunosorbent assays for IgG,
IgM, and the IgG avidity index.
LIAISON system. The LIAISON immunoassay analyzer is a fully automated
random-access analyzer. Its test principle is based on magnetic microparticle
technology, chemiluminescence with flash light kinetics, and an isoluminol de-
rivative as a label. The analyzer is a benchtop system with a loading capacity of
144 samples and is designed to handle primary tubes with bar code identification.
Continuous reloading is possible, as the samples are placed in 12-tube racks.
Samples and reagents are transferred via pipetting needles. The sample volumes
used in the assays tested in this study varied between 20 and 30 l. Reagents
required for 100 determinations (LIAISON Toxoplasma-specific IgG and LIAI-
SON Toxoplasma-specific IgM assays) or 25 determinations (LIAISON Toxo-
plasma-specific IgG avidity assay) are assembled in one integrated reagent car-
tridge (Reagent Integral) identified by bar-coded labeling, providing information
such as parameter information, lot number with expiration date, and recalibra-
tion data. The liquid levels of samples, reagents, starter reagents. and system
fluid are checked via sensors. The reagents are stored in a cooled, temperature-
controlled area and can be continuously reloaded. Up to 15 different kits can be
loaded simultaneously. All reagents (magnetic particles, luminescence-labeled
tracer, two calibrators, diluent, and assay buffer) are provided ready to use. The
walk-away time is at least 6 h. The average throughput is 100 to 140 tests per
hour.
The instrument offers variable assay- or patient-specific dilution protocols. The
user interface is Windows-based software with both touch screen and keyboard
operations. The chemiluminescence signal is generated by the addition of two
trigger solutions, and light is quantified as relative light units. Data reduction is
based on a master curve with a two-point recalibration method. Calibration
allows recalculation of the working standard curve from the stored master stan-
dard curve and is performed every 4 weeks with two calibrators in triplicate. A
maximum of four calibrations can be performed for every reagent integral.
Parameter-specific LIAISON control sera obtained from human serum pools are
available from the manufacturer.
Toxoplasma-specific IgG antibodies. The LIAISON Toxoplasma-specific IgG
assay is completed in 35 min. Toxoplasma antigen from a whole-cell lysate is used
to coat the solid phase (paramagnetic particles). During the first incubation step,
serum or plasma is added to the magnetic particles, incubated for 10 min, and
washed three times. A monoclonal IgG antibody to human IgG coupled to an
isoluminol derivative is added and incubated with the solid phase for a further 10
min. After washing is done, the chemiluminescence signal is generated. The assay
is calibrated against the World Health Organization Third International Toxo-
plasma reference standard, and the measurement range is 0 to 500 IU/ml.
Positive results are defined as values above 8 IU/ml, borderline results range
from 6 to 8 IU/ml, and negative results are defined as values below 6 IU/ml.
Toxoplasma-specific IgM antibodies. The LIAISON Toxoplasma-specific IgM
assay is completed in 35 min. A monoclonal IgG antibody to human IgM is used
to coat the paramagnetic particles. During the first incubation step, serum or
plasma is added to the magnetic particles, incubated for 10 min, and washed. A
soluble Toxoplasma antigen obtained from a whole-cell lysate is added with a
monoclonal IgG antibody to T. gondii surface antigen 1 labeled with an isolu-
minol derivative and incubated with the solid phase for a further 10 min. After
washing is done, the chemiluminescence signal is generated. The measurement
range is between 0 and 160 arbitrary units (AU)/ml. Positive results are defined
as values above 8 AU/ml, borderline results range from 6 to 8 AU/ml, and
negative results are defined as values below 6 AU/ml.
Toxoplasma-specific IgG avidity index. The LIAISON Toxoplasma-specific IgG
avidity assay is completed in 40 min. The avidity index is measured by including
a wash step in the IgG test described above; in this step, low-avidity IgG anti-
bodies are eluted from the Toxoplasma antigen with 6 M urea buffer. The
measurement range is an IgG avidity index of 0.010 and 0.950, calculated as the
ratio of the units in the sample treated with 6 M urea buffer to the units in the
nontreated sample. The avidity index allows specimen classification as low (avid-
ity index, 0.2), moderate (avidity index, 0.020 to 0.25), or high (avidity index,
0.25) avidity. A high avidity index excludes infections within the previous 4
months.
Statistical analysis. Means were compared with a two-tailed t test assuming a
normal distribution and independent variance.
RESULTS
The LIAISON system was easy to use, and the integration of
the IgG avidity index into the procedure was convenient and
time-saving. The LIAISON system is the first system which
allows measurement of the IgG avidity index for samples with
low levels of IgG antibodies. Not all centers compared the
LIAISON system to other systems, and one center compared it
to in-house assays.
The Sabin-Feldman dye test measures all immunoglobulin
subclasses, and the results of this test therefore cannot be
compared to the results of isolated IgG or IgM assays but only
to combined IgG and IgM results.
Table 1 shows a comparison of the results of the Sabin-
Feldman dye test and the combined IgG and IgM results ob-
tained with the LIAISON system. Assuming that the dye test is
the reference standard, the LIAISON system showed a sensi-
tivity of 99.3%, a specificity of 96.8%, a positive predictive
value of 98.9%, and a negative predictive value of 98.1% (Ta-
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ble 1). The agreement between the LIAISON system com-
bined IgM and IgG results and the Sabin-Feldman dye test
results was 99%.
Table 2 shows a comparison of the LIAISON IgM assay and
the ISAGA IgM, VIDAS IgM, AXSYM IgM, and Platelia IgM
assays. The agreements were 96% with the ISAGA IgM, 95%
with the AXSYM IgM and Platelia IgM, and 97% with the
VIDAS IgM assays.
Table 3 shows a comparison of the LIAISON IgG assay and
the VIDAS IgG, AXSYM IgG, and Platelia IgG assays. The
agreements were 91% with the AXSYM IgG and 100% with
both the Platelia IgG and the VIDAS IgG assays.
The LIAISON Toxoplasma-specific IgG avidity index was
measured for 103 samples from three centers where the date of
seroconversion was available. Within the first 4 months, only 2
of 77 samples from pregnant women had an IgG avidity index
above 0.25 (Fig. 1). A number of samples continued to show a
low IgG avidity index more than 4 months after infection.
The LIAISON Toxoplasma-specific IgG avidity index was
compared with the results of the VIDAS system, and the cor-
relation is shown in Fig. 2; the correlation coefficient was 0.81.
A total of 32 samples were obtained from individuals who
were diagnosed with acute T. gondii infection but were not
pregnant and therefore were not treated (data not included in
Fig. 1). The mean IgG avidity index in treated pregnant women
infected within the preceding 16 weeks was 0.092 (standard
deviation, 0.047), and that for nontreated nonpregnant indi-
viduals was 0.149 (standard deviation, 0.077) (P value deter-
mined by a two-tailed t test, 0.0086). There was no significant
difference between the two groups at 16 weeks after infection
(P value determined by a two-tailed t test, 0.90), but the sample
size may have been too small to identify a difference.
DISCUSSION
Analysis of Toxoplasma-specific IgM and IgG antibodies
with the LIAISON IgG and IgM combination showed a good
correlation with the dye test. The dye test measures total spe-
cific immunoglobulins, including IgG, IgM, and IgA, and the
good correlation between the dye test and the LIAISON IgG
and IgM combination indicates that the LIAISON Toxoplas-
ma-specific IgM assay is able to detect low levels of IgM seen
at the beginning of infection.
TABLE 1. Comparison of Sabin-Feldman dye test and LIAISON
Toxoplasma-specific IgG- and IgM assays with 613 samples
Sabin-Feldman
dye test result
No. of samples with the following LIAISON IgG
and/or IgM assay result:
Positive Equivocal Negative Total
Positive 446 3 3 452
Negative 5 3 153 161
Total 451 6 156 613
TABLE 2. Comparison of LIAISON IgM and other assays
for T. gondii-specific IgM antibodies
Assay Cutoff
No. of samples with the following
LIAISON IgM assay result:
Positive Equivocal Negative Total
ISAGA IgM 9–12 265 6 9 280
6–8 8 0 0 8
6 12 2 249 263
Total 285 8 258 551
AXSYM IgM Positive 10 0 2 12
Equivocal 0 0 0 0
Negative 3 0 92 95
Total 13 0 94 107
VIDAS IgM Positive 39 4 4 47
Equivocal 0 0 0 0
Negative 5 3 253 261
Total 44 7 257 308
Platelia IgM Positive 61 8 3 72
Equivocal 0 0 0 0
Negative 3 1 68 72
Total 64 9 71 144
TABLE 3. Comparison of LIAISON IgG and other assays
for T. gondii-specific IgG antibodies
Assay Cutoff
No. of samples with the following
LIAISON IgG assay result:
Positive Equivocal Negative Total
AXSYM IgG Positive 18 1 10 29
Equivocal 0 0 0 0
Negative 0 0 89 89
Total 18 1 99 118
VIDAS IgG Positive 184 2 1 187
Equivocal 1 1 0 2
Negative 0 1 305 306
Total 185 4 306 495
Platelia IgG Positive 142 0 0 142
Equivocal 0 0 0 0
Negative 0 0 38 38
Total 142 0 38 180
FIG. 1. Development of the LIAISON IgG avidity index in 103
pregnant and treated women monitored after infection (seroconver-
sion) (Brussels, Paris, and Pavia). The cutoff levels are indicated for
the IgG avidity index and for the time after infection (see Materials
and Methods).
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A comparison with the ISAGA IgM assay showed that nine
samples were negative in the LIAISON IgM assay but positive
in the ISAGA IgM assay, confirming that the ISAGA IgM
assay is more sensitive than the LIAISON IgM assay. It is well
known that low levels of Toxoplasma-specific IgM antibodies
are a common problem in the diagnosis of acute toxoplasmosis
(23).
The Sabin-Feldman dye test has traditionally been used to
estimate the time of infection because the DT increases for
approximately the first 8 weeks after infection; however, the
dye test is expensive and difficult to perform and standardize,
and only a limited number of laboratories perform it on a rou-
tine basis (22). The concept of measuring Toxoplasma-specific
IgG antibody maturation as the immune response evolves was
introduced for T. gondii by Hedman et al. (8), who showed that
sera collected from infected patients up to 3 months after
infection could be distinguished from those collected later.
The IgG avidity index is not standardized between labora-
tories, and no external quality assurance program includes the
Toxoplasma-specific IgG avidity index. We do not know much
about the variability and reproducibility of the index, but mod-
eling has shown wide confidence intervals, and it is not known
whether the avidity-maturation curve is linear over time (1).
The maturation of the IgG response varies considerably be-
tween individuals. In a study by Lappalainen et al. (14), two
seroconverting mothers already had an IgG avidity index above
20% at the time of diagnosis, but most patients had developed
an IgG avidity index above 15% after 180 days (14). A study
from France found an average IgG avidity index of 0.2 in
pregnant women infected within 5 months (15).
The original method developed by Hedman et al. (8) used
serial dilutions tested in an enzyme immunoassay with and
without 6 M urea, but automated assays today calculate the
IgG avidity index from two single measurements of a sample
with and without urea. This process introduces uncertainty,
although experiments with only two dilutions showed excellent
agreement with IgG avidity measurements obtained with four
serial dilutions (13). Testing of a single dilution with and with-
out urea was further evaluated by Prince and Wilson (21), who
showed that because the signal obtained in an enzyme immu-
noassay system is not linear, it makes a difference whether the
Toxoplasma-specific IgG avidity index is calculated from opti-
cal densities or activities measured in international units of
Toxoplasma-specific IgG antibodies per milliliter (21).
The avidity results found here showed that a persistent, low
IgG avidity index is seen in many patients even more than 4
months after infection. Thus, a low IgG avidity index does not
predict infection within the preceding 4 months, but a high IgG
avidity index almost always excludes infection within the pre-
ceding 4 months in treated pregnant women and within 2
months in nontreated nonpregnant individuals.
It is necessary to know the date of infection to evaluate the
performance of Toxoplasma-specific IgG avidity index assays.
Up to half of patients with acute infections may show a low or
borderline IgG avidity index 6 months after the infection (19,
24), in concordance with the results reported here. The LIAI-
SON system was compared with the semiautomated VIDAS
system for measuring the Toxoplasma-specific IgG avidity in-
dex; there was a good correlation between the results of the
two systems, indicating that the persistence of low-level Toxo-
plasma-specific IgG antibodies is a problem inherent in mea-
suring the Toxoplasma-specific IgG avidity index and is unre-
lated to the assay system.
We found one sample within the first 4 months after infec-
tion with an IgG avidity index just above 0.25. This finding is
rare but has also been reported in other studies. For instance,
the cutoff for the Toxoplasma-specific IgG avidity index in the
VIDAS system was defined as 0.3 to ensure that all sera from
acute infections had a low-avidity index (20). The same study
showed that at least in pregnant women, a low IgG avidity
index persisted for up to 9 months after infection, and all
women were treated.
In a study of T. gondii-infected pregnant women identified
prospectively through prenatal screening, Jenum et al. (11)
found that 2 out of 73 women had an IgG avidity index above
0.2 before 20 weeks after infection, but many continued to
have a low IgG avidity index even 1 year after infection. It is
assumed that all women were treated during pregnancy.
The definition of a low IgG avidity index differs markedly
between different studies, and one study found that patients
infected within the preceding 3 months had an IgG avidity
index below 0.45 (10). A comparison of the VIDAS and Lab-
systems IgG avidity index assays showed correlation coeffi-
cients of 0.6 for pregnant women and 0.88 for other patients
(2), but the difference was not discussed further. Improvement
of the IgG avidity assay with the Western blot technique was
attempted and revealed differences in the maturation of spe-
cific IgG antibodies to different antigens (26).
The observation that T. gondii-specific IgG maturation is
delayed in treated pregnant women compared to nontreated
individuals was reported in one previous study, which found
significantly delayed IgG maturation in treated individuals
(25). Our finding that treatment may influence IgG maturation
emphasizes the need for further studies to better clarify the
avidity maturation process in pregnant women receiving ther-
apy in comparison with nontreated individuals. Depending on
the results of such studies, different cutoff values may have to
be defined for treated and nontreated persons.
By use of Toxoplasma-specific IgG assays in combination
with specific IgM antibodies, the diagnosis of T. gondii infec-
tion in early pregnancy has been improved significantly (23).
FIG. 2. Correlation (r  0.81) between the T. gondii-specific IgG
avidity indexes measured by the LIAISON and VIDAS systems.
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The LIAISON system is a valuable system for the exclusion
of recently acquired infection with T. gondii (less than 4 months)
in pregnant women and decreases significantly the necessity for
follow-up testing.
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